Clinical Trials Directory

Trials / Conditions / Neurofibroma, Plexiform

Neurofibroma, Plexiform

14 registered clinical trials studyying Neurofibroma, Plexiform — 4 currently recruiting.

StatusTrialSponsorPhase
RecruitingPAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
NCT06961565
Pasithea Therapeutics Corp.Phase 1
RecruitingReal-World Treatment Study of Koselugo (Selumetinib)
NCT06360406
AstraZeneca—
Active Not RecruitingObservational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs
NCT06175637
AstraZeneca—
RecruitingEvaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibro
NCT05199376
Centre Leon BerardN/A
Active Not RecruitingA Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoper
NCT04590235
AstraZenecaPhase 1
Active Not RecruitingTreatment of NF1-related Plexiform Neurofibroma With Trametinib
NCT03741101
Region SkanePhase 2
CompletedMedication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatm
NCT03531814
National Cancer Institute (NCI)N/A
WithdrawnStudy of Imatinib in Children With Neurofibromatosis and Airway Tumors
NCT03688568
Indiana UniversityPhase 2
WithdrawnClinical Sequencing of Cancer and Tissue Repository: OncoGenomics
NCT03027401
National Cancer Institute (NCI)—
RecruitingPhase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and
NCT02390752
National Cancer Institute (NCI)Phase 1
Active Not RecruitingAZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
NCT01362803
National Cancer Institute (NCI)Phase 1 / Phase 2
CompletedPirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
NCT00076102
National Cancer Institute (NCI)Phase 2
CompletedR115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
NCT00021541
National Cancer Institute (NCI)Phase 2